Treating Duchenne means hope to share meaningful moments

For people with Duchenne muscular dystrophy amenable to exon 53 skipping: VILTEPSO is proven to increase dystrophin, a key protein for supporting muscle health*

Jordan (15 years old), a real VILTEPSO patient and compensated spokesperson.
*In a clinical study, 100% of patients taking VILTEPSO showed an increase in dystrophin levels.
Average dystrophin level increase to nearly 6% at week 25 of treatment vs 0.6% before treatment.
See Efficacy & Safety Data

What Is DMD?
How VILTEPSO Works
Taking VILTEPSO

WHAT IS DMD?

Duchenne muscular dystrophy (DMD) is a rare genetic disease that results in muscles becoming damaged and weaker over time.

mRNA Icon

DMD is caused by a missing or mutated part of the gene that produces dystrophin.

Protein Icon

With a mutation or deletion in the DMD gene, the body produces unusable dystrophin that can’t properly support muscle function.

Clock Icon

EARLY DIAGNOSIS IS KEY to helping manage progressive muscle weakness and functional decline in patients with DMD.

For muscles to function properly, they need a protein called DYSTROPHIN

EFFICACY & SAFETY

Learn about VILTEPSO’s efficacy data, and
the four-year, open-label extension study

See Efficacy & Safety Data

How VILTEPSO Works

VILTEPSO is proven to help the body make
a shortened form of dystrophin protein

Exon 53

1. Healthy DMD Gene

The Duchenne muscular dystrophy (DMD) gene is made up of individual pieces called exons. These exons work together like building blocks to tell the body how to make a full-length dystrophin protein.

Exon 53 missing exon

2. DMD Gene Mutation

A mutation or deletion in the DMD gene may impact the way its exons fit together. As you can see above, exon 53 has lost its connecting partner, which prevents the body from making enough usable dystrophin to support skeletal muscles.

Skipped exon

3. EXON 53 Skipping

In DMD patients amenable to exon 53 skipping, VILTEPSO is designed to skip over exon 53. In this case, it skips over the orange block (exon 53) so that the green block can fit next to the blue one.

Exon skipping 53

4. Shortened Dystrophin

By skipping exon 53, VILTEPSO helps the body make a shortened but partially functional form of dystrophin protein.

When is a child’s exon deletion amenable to exon-skipping therapy?

For children diagnosed with DMD, a simple genetic test can identify their specific mutation, which may fall within one of many exon ranges amenable to (eligible for) an exon-skipping therapy such as VILTEPSO.

The Exon Finder Tool demonstrates how this works. Just select an exon range below based on the results of the genetic test, and it can tell you if exon-skipping therapy is an option.

Exon Finder Tool

Select an exon range from the options listed below:

3-50

4-50

5-50

6-50

9-50

3-52

4-52

5-52

6-52

9-52

10-50

11-50

13-50

14-50

15-50

16-50

17-50

19-50

10-52

11-52

13-52

14-52

15-52

16-52

17-52

19-52

21-50

23-50

24-50

25-50

26-50

27-50

28-50

29-50

21-52

23-52

24-52

25-52

26-52

27-52

28-52

29-52

30-50

31-50

32-50

33-50

34-50

35-50

36-50

37-50

38-50

39-50

30-52

31-52

32-52

33-52

34-52

35-52

36-52

37-52

38-52

39-52

40-50

41-50

42-50

43-50

45-50

47-50

48-50

49-50

40-52

41-52

42-52

43-52

45-52

47-52

48-52

49-52

50

52

52-58

52-61

52-63

52-64

52-66

52-76

52-77

50-52

54-58

54-61

54-63

54-64

54-66

54-76

54-77

This tool is not intended to deliver a diagnosis or to replace any discussions with your doctor or genetic counselor.

Can’t find your range?

This child may not be eligible for exon-skipping therapy—consult a doctor for more information.

The selected range of exon deletions suggests this child may be eligible for treatment with VILTEPSO!

If your child has been diagnosed with DMD, speak with a doctor about VILTEPSO.

Email me this recommendation

VILTEPSO: an exon-skipping therapy option

  • Designed to bind to and induce skipping of exon 53 of the dystrophin pre-mRNA, resulting in the production of a shortened dystrophin protein that contains essential functional portions
  • Patients taking VILTEPSO showed a mean increase in dystrophin levels to 5.9% of normal by week 25 vs 0.6% of normal at baseline
  • 100% of patients showed an increase in dystrophin levels
  • VILTEPSO can be used to treat patients with DMD with an exon 52 deletion

This selected range of exon deletions suggests this child may be eligible for treatment with an exon-skipping therapy.

If your child has been diagnosed with DMD, speak with a doctor about potential treatment options.

What is exon skipping?

  • Exon skipping is a genetic technique that assists in “skipping over” an exon
  • Exon skipping can be used to treat specific exon deletions

Sign up to receive updates about VILTEPSO

Keep up to date on our latest news and developments.

Stay Informed

Discover NS Support and find links to helpful resources

We’re committed to being a partner to families coping with DMD.

Get Support

Interested in clinical trials for Duchenne muscular dystrophy?

To inquire about ongoing or future VILTEPSO clinical trials, please click the button below to contact us.

Contact Us

Meet the VILTEPSO Ambassadors

Hear and read what real patients and their families have to say about life and treatment with VILTEPSO.

See Patient Stories

Taking VILTEPSO

VILTEPSO is a once-weekly intravenous (IV) infusion that can be given by a healthcare professional at home or at a treatment center.

Here are a few questions you may have about taking VILTEPSO:

IV Icon

Q:

What is an infusion?

A:

An IV infusion goes into the patient’s bloodstream through a small needle and tube. It is a FAST way to get medication directly into the body.

Scale Icon

Q:

How much medication is in each VILTEPSO dose?

A:

A healthcare provider will calculate the dose based on the patient’s body weight. 80 MILLIGRAMS of VILTEPSO is given for each kilogram (a kilogram is approximately 2.2 pounds) of weight per week.

Clock Icon

Q:

How long is the infusion?

A:

The infusion lasts 60 MINUTES. But plan for some extra time before and after treatment in case there are questions for the nurse, or the patient needs post-treatment observation.

You can download our helpful guide to starting VILTEPSO, along with our infusion overview guide.

Getting Started With VILTEPSO VILTEPSO Infusion Overview
Alert Icon

REMEMBER, A DOCTOR IS ALWAYS YOUR BEST RESOURCE FOR information about DMD and determining if VILTEPSO could be the right treatment option for you.

For more information about DMD, exon skipping, and VILTEPSO, you can download the Caregiver and Patient Guide

For suggested questions to ask your doctor about DMD, exon skipping, and VILTEPSO, you can download the Doctor Discussion Guide

Toggle ISI Open EXPAND

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
  • You are encouraged to report adverse events related to VILTEPSO. To do so, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276).

For more information about VILTEPSO, see full Prescribing Information.

For more information about VILTEPSO, see full Prescribing Information.